Category: Health Care

How are you feeling today? Keep up to date on news and stories related to health care here!

Business, Health Care

Bristol Myers Squibb showcases research advancing outcomes addressing hard-to-treat blood cancers and diseases across small molecule, biologic and cell therapies at ASH 2020

Results for our CD19-targeted CAR T cell therapy lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia Data showcasing BCMA-targeted CAR T cell therapy idecabtagene vicleucel (ide-cel), including updated results from the Phase 1 CRB-401

Business, Health Care

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) demonstrated statistically significant improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) versus Sunitinib as first-line treatment for patients…

LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib Results of Investigational Phase 3 KEYNOTE-581/CLEAR Trial (Study 307) to be Presented at Upcoming Medical Meeting KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK): KEYTRUDA®

Business, Health Care

Bristol Myers Squibb presents late-breaking Phase 2 data demonstrating the safety and efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis

Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints Deucravacitinib was well-tolerated with

Business, Health Care

Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy for first-line treatment of metastatic non-small cell lung cancer

Approval based on Phase 3 CheckMate -9LA trial results showing superior overall survival in patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression or tumor histologies European Commission decision marks the first time a dual immunotherapy with limited chemotherapy is

Business, Health Care

Catalent, Inc. reports first quarter fiscal 2021 results

 Q1’21 net revenue of $845.7 million increased 27% as-reported, or 26% in constant currency, compared to Q1’20. On an organic basis, constant currency net revenue in Q1’21 grew 20% compared to Q1’20.  Q1’21 Adjusted EBITDA of $174.4 million increased 37% as-reported, or

Business, Health Care

DESTINY-Breast05 head-to-head phase 3 trial of ENHERTU® versus T-DM1 initiated in patients with HER2 positive early breast cancer at high risk after neo-adjuvant therapy

TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of DESTINY-Breast05, a global phase 3, head-to-head trial of ENHERTU® (fam-trastuzumab deruxtecan-nxki) versus ado-trastuzumab emtansine (T-DM1) as adjuvant therapy in patients with

Business, Health Care

LianBio announces $310 million crossover financing

Supported by a strong U.S. and Chinese investor syndicate including Perceptive Advisors, RA Capital, Venrock Healthcare Capital Partners and CMG-SDIC Capital Proceeds will fund advancement of the Company’s global innovation mining platform and diversified portfolio of product candidates SHANGHAI & PRINCETON, N.J.–(BUSINESS